OLIPASS CORPORATION
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
244460 | KO
Overview
Corporate Details
- ISIN(s):
- KR7244460002
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 동백중앙로16번길 16-4 에이스동백타워1동 20층, 용인시
Description
OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-24 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.5 KB | ||
| 2021-12-20 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득(제9회차)
|
Korean | 10.8 KB | ||
| 2021-12-17 00:00 |
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 11.6 KB | ||
| 2021-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2021-12-16 00:00 |
임시주주총회결과
|
Korean | 13.6 KB | ||
| 2021-12-16 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.5 KB | ||
| 2021-12-03 00:00 |
기업설명회(IR)개최
|
Korean | 7.7 KB | ||
| 2021-12-02 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2021-11-26 00:00 |
주주총회소집공고
|
Korean | 71.6 KB | ||
| 2021-11-26 00:00 |
의결권대리행사권유참고서류
|
Korean | 60.6 KB | ||
| 2021-11-12 00:00 |
분기보고서 (2021.09)
|
Korean | 1.1 MB | ||
| 2021-10-28 00:00 |
주주총회소집결의
|
Korean | 13.8 KB | ||
| 2021-10-28 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.5 KB | ||
| 2021-10-26 00:00 |
기타경영사항(특허권취득)(자율공시)(티로시나제 안티센스 올리고뉴클레오타이드)
|
Korean | 5.3 KB | ||
| 2021-10-13 00:00 |
투자판단관련주요경영사항(비마약성진통제(OLP-1002) 호주 임상 2a상 시험 계획 승인)
|
Korean | 10.0 KB |
Automate Your Workflow. Get a real-time feed of all OLIPASS CORPORATION filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OLIPASS CORPORATION
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OLIPASS CORPORATION via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
